TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$10.68 0.00 (0.00%) As of 10/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Knight Therapeutics Stock (TSE:GUD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's RangeC$10.65▼C$10.8450-Day RangeC$9.21▼C$10.8352-Week RangeC$5.66▼C$11.00Volume93,745 shsAverage Volume94,346 shsMarket CapitalizationC$1.05 billionP/E Ratio71.20Dividend YieldN/APrice TargetC$9.50Consensus RatingBuy Company Overview Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca. Read More Knight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreGUD MarketRank™: 0.585834649815 of 5 starsKnight Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Downside RiskKnight Therapeutics has a consensus price target of C$9.50, representing about 11.0% downside from its current price of C$10.68.Amount of Analyst CoverageKnight Therapeutics has received no research coverage in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is 71.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is 71.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 206.66.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GUD. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentKnight Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions22.75% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUD Stock News HeadlinesKnight Therapeutics Announces Regulatory Approval of NIKTIMVO in BrazilOctober 7, 2026 | marketscreener.comMKnight Therapeutics Announces Launch of TAVALISSE® in BrazilOctober 6, 2026 | markets.businessinsider.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Knight Therapeutics Inc.September 30, 2026 | barrons.comKyowa Kirin, Knight Therapeutics Enter Distribution Deal For POTELIGEO In Latin AmericaSeptember 29, 2026 | rttnews.comKyowa Kirin Signs Exclusive POTELIGEO Distribution Deal With KnightSeptember 29, 2026 | rttnews.comKyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin AmericaSeptember 29, 2026 | finance.yahoo.comKnight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)September 29, 2026 | markets.businessinsider.comSee More Headlines GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$6.05 on January 1st, 2026. Since then, GUD stock has increased by 76.5% and is now trading at C$10.68. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.03) EPS for the quarter. The firm earned $143.97 million during the quarter. Knight Therapeutics had a trailing twelve-month return on equity of 1.91% and a net margin of 2.72%. Read the conference call transcript. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include Enbridge (ENB), Suncor Energy (SU), Royal Bank of Canada (RY), Canadian Pacific Kansas City (CP), TELUS (T), Manulife Financial (MFC) and ARC Resources (ARX). Company Calendar Last Earnings8/06/2026Today10/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:GUD CIKN/A Webwww.knighttx.com Phone514-484-4483FaxN/AEmployees830Year FoundedN/APrice Target and Rating Average Price Target for Knight TherapeuticsC$9.50 High Price TargetC$9.50 Low Price TargetC$9.50 Potential Upside/Downside-11.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C$0.15 Trailing P/E Ratio71.20 Forward P/E Ratio105.80 P/E Growth-1013.5Net Income-C$30.73 million Net Margins2.72% Pretax MarginN/A Return on Equity1.91% Return on Assets0.51% Debt Debt-to-Equity Ratio4.29 Current Ratio2.28 Quick Ratio1.79 Sales & Book Value Annual SalesC$547.31 million Price / Sales1.92 Cash FlowC$2.78 per share Price / Cash Flow3.85 Book ValueC$8.13 per share Price / Book1.31Miscellaneous Outstanding Shares98,232,000Free FloatN/AMarket CapC$1.05 billion OptionableNot Optionable Beta-0.45 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (TSE:GUD) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
